BioVerse #26 - Annual Review of Asian Biotech - China Takes the Central Stage

Join us for an insightful webinar hosted by Leon Tang, featuring industry leaders Jens Norhave and Franck Le Deu. Discover the latest trends in Asian biotech, with a spotlight on China’s outbound licensing deals, IPO market dynamics, and regulatory updates.

Explore case studies, innovative co-development models, and future strategies for success. Don’t miss insights on geopolitics, market access, and what’s next for Asian biotech. Engage with experts and participate in a live Q&A session. Reserve your spot today.

Timestamp agenda:
00:00:00 Introduction of BioVerse.
00:02:57 Self introduction of the speakers.
00:05:30 Annual Review of Asian Biotech: focused on East-West collaboration and East-East collaborations.
00:11:30 Overview of China-to-West BD&L Summary in 2025.
00:15:35 Jens Norhave summarizes HengRui's record-breaking licensing deals, at least 5 publicly disclosed ones.
00:25:40 Franck Le Deu summarizes the fundamental factors that drive China's licensing boom and highlights 2 deals.
00:34:55 Leon Tang comments on the story of OTR Therapeutics record-breaking R&D speed.
00:39:10 The capital market of Asian biotech - HKEX is the best performing in the world.
00:49:30 Update of Asian biotech regulatory landscape - focus on China's streamlined investigator-initiated trials in China,
00:52:28 Improved market access of Asian markets and how China-based companies can access global markets, especially the US market.
00:58:40 Drug development is like baking a cake, you need Great Recipe, Experienced Chefs, and Cost-Effective Kitchen staffed with hard-working assistants. East-West collaboration will follow this novel business model and competitive advantages.
1:00:40 Geopolitics impact on China-West licensing.
1:05:10 Q&A
1:09:30 Visit our LinkedIn page to find all the referenced sources:   / 7402695125874778112  

Request for the PDF of the presentation can be sent to [email protected]